Sotera Health Yönetim

Yönetim kriter kontrolleri 3/4

Sotera Health CEO'su Michael Petras, Jun2016 tarihinde atandı, in görev süresi 8.42 yıldır. in toplam yıllık tazminatı $ 9.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.8% maaş ve 89.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.91% ine doğrudan sahiptir ve bu hisseler € 80.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.1 yıl ve 4 yıldır.

Anahtar bilgiler

Michael Petras

İcra Kurulu Başkanı

US$9.7m

Toplam tazminat

CEO maaş yüzdesi	10.8%
CEO görev süresi	8.4yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	4.1yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Petras'un ücretlendirmesi Sotera Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$70m
Jun 30 2024	n/a	n/a	US$40m
Mar 31 2024	n/a	n/a	US$55m
Dec 31 2023	US$10m	US$1m	US$51m
Sep 30 2023	n/a	n/a	-US$306m
Jun 30 2023	n/a	n/a	-US$268m
Mar 31 2023	n/a	n/a	-US$261m
Dec 31 2022	US$17m	US$1m	-US$234m
Sep 30 2022	n/a	n/a	US$121m
Jun 30 2022	n/a	n/a	US$123m
Mar 31 2022	n/a	n/a	US$135m
Dec 31 2021	US$2m	US$1m	US$115m
Sep 30 2021	n/a	n/a	US$36m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$17m	US$728k	-US$39m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	US$2m	US$700k	-US$21m

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 9.70M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.14M ).

Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Michael Petras (55 yo)

8.4yrs

Görev süresi

US$9,701,005

Tazminat

Mr. Michael B. Petras Jr., serves as Chief Executive Officer at Sotera Health Company since June 20, 2016. He has been Chairman of the Board at Sotera Health Company since October 2020. He also served as t...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Petras	Chairman & CEO	8.4yrs	US$9.70m	1.91% € 80.7m
Jonathan Lyons	Senior VP & CFO	1.4yrs	US$2.18m	0.039% € 1.6m
Alexander Dimitrief	Senior VP	2yrs	US$862.18k	0.083% € 3.5m
Michael Rutz	President of Sterigenics	4.1yrs	US$2.03m	0.17% € 7.1m
Robert Hauzie	Chief Information Officer	5.8yrs	Veri yok	Veri yok
Kristin Gibbs	Chief Marketing Officer	8yrs	Veri yok	Veri yok
William Lehmann	Senior Vice President of Strategy & Corporate Development	2.8yrs	Veri yok	Veri yok
Sally Turner	Chief Human Resources Officer	5.8yrs	Veri yok	Veri yok
Danielle Menture	Senior Vice President of Global Environmental	less than a year	Veri yok	Veri yok
Joseph Shrawder	President of Nelson Labs	4.1yrs	Veri yok	Veri yok
Riaz Bandali	President of Nordion	2.8yrs	Veri yok	Veri yok
Jason Peterson	VP & Treasurer	no data	Veri yok	Veri yok

4.1yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: SH5 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Petras	Chairman & CEO	8.4yrs	US$9.70m	1.91% € 80.7m
James Neary	Independent Director	4.1yrs	US$320.00k	0.015% € 620.0k
Constantine Mihas	Independent Director	4.1yrs	US$305.00k	0.015% € 620.0k
Sean Cunningham	Independent Director	4.1yrs	US$302.50k	0.015% € 620.0k
Vincent Petrella	Independent Director	4yrs	US$325.00k	0.015% € 620.0k
Christopher Simon	Independent Director	less than a year	Veri yok	Veri yok
Ann Klee	Independent Director	4.1yrs	US$322.50k	0.031% € 1.3m
Robert Knauss	Independent Director	2.1yrs	US$300.00k	0.0056% € 234.6k
Ruoxi Chen	Independent Director	4yrs	US$302.50k	0.015% € 620.0k
David Wheadon	Independent Director	3.5yrs	US$310.00k	0.013% € 532.5k
Karen Flynn	Independent Director	less than a year	US$9.99k	Veri yok

4.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SH5 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Sotera Health Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sotera Health Appoints Christopher Simon to the Board of Directors

Sotera Health Appoints Karen Flynn to Board of Directors

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

High number of new and inexperienced directors

Sotera Health Company Announces Board Changes

Recent updates

Third quarter 2024 earnings released: EPS: US$0.06 (vs US$0.049 loss in 3Q 2023)

Sotera Health Company to Report Q3, 2024 Results on Nov 05, 2024

Sotera Health Company has completed a Follow-on Equity Offering in the amount of $375.75 million.

Sotera Health Company has filed a Follow-on Equity Offering.

Second quarter 2024 earnings released: EPS: US$0.031 (vs US$0.083 in 2Q 2023)

Sotera Health Company Reaffirms Earnings Guidance for the 2024

Sotera Health Appoints Christopher Simon to the Board of Directors

Sotera Health Company to Report Q2, 2024 Results on Aug 05, 2024

Sotera Health Company Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024

First quarter 2024 earnings released: EPS: US$0.022 (vs US$0.01 in 1Q 2023)

Sotera Health Company to Report Q1, 2024 Results on May 02, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

Sotera Health Company has completed a Follow-on Equity Offering in the amount of $368.75 million.

Sotera Health Company Provides Revenue Guidance for the Full-Year 2024

Sotera Health Company has filed a Follow-on Equity Offering.

Full year 2023 earnings released: EPS: US$0.18 (vs US$0.83 loss in FY 2022)

Sotera Health Company to Report Q4, 2023 Results on Feb 27, 2024

Sotera Health Company Provides Preliminary Revenue Guidance for the Year 2023

Sotera Health Appoints Karen Flynn to Board of Directors

Sotera Health Company Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.089 profit in 3Q 2022)

Sotera Health Company to Report Q3, 2023 Results on Nov 01, 2023

Sotera Health Company Revises Updated Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.084 (vs US$0.11 in 2Q 2022)

Now 21% undervalued after recent price drop

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

Sotera Health Company Appoints Jon Lyons as Chief Financial Officer

New minor risk - Share price stability

Sotera Health Company Re-Affirms Revenue Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 in 1Q 2022)

Now 23% undervalued after recent price drop

Now 21% undervalued

Now 22% undervalued

Full year 2022 earnings released: US$0.83 loss per share (vs US$0.41 profit in FY 2021)

Sotera Health Company to Report Q4, 2022 Results on Feb 28, 2023

Sotera Health Company Reaffirms Earnings Guidance for the Year Ended December 31, 2022

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company

Investor sentiment improved over the past week

Sotera Health Company Announces Settlement of Ethylene Oxide Litigation in Illinois

Investor sentiment improved over the past week

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.09 (vs US$0.098 in 3Q 2021)

Sotera Health Company Revises Earnings Guidance for the Full Year 2022

Sotera Health Company to Report Q3, 2022 Results on Nov 02, 2022

Sotera Health Company Announces Board Changes

Investor sentiment deteriorated over the past week

Sotera Health Company Announces Executive Changes, Effective October 1, 2022

Second quarter 2022 earnings released: EPS: US$0.11 (vs US$0.15 in 2Q 2021)

Sotera Health Company Revises Earnings Guidance for the Full Year 2022

Sotera Health Company Announces Executive Changes

Investor sentiment improved over the past week

Sotera Health Company Announces Departure of Scott Leffler as Chief Financial Officer, Effective August 12, 2022

First quarter 2022 earnings released: EPS: US$0.11 (vs US$0.038 in 1Q 2021)

Sotera Health Company Reaffirms Earnings Guidance for the Year 2022

High number of new and inexperienced directors

Sotera Health Company to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Sotera Health Company, Annual General Meeting, May 26, 2022

Sotera Health Company Announces Earning Guidance for Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sotera Health Company to Report Q4, 2021 Results on Mar 01, 2022

Sotera Health Company Updates Revenue Guidance for the Full-Year 2021

President of Sterigenics recently sold €1.4m worth of stock

Second quarter 2021 earnings released: EPS US$0.15 (vs US$0.03 in 2Q 2020)

Sotera Health Company Reaffirms Earnings Guidance for the Year 2021

Sotera Health Company(NasdaqGS:SHC) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.039 (vs US$0.011 in 1Q 2020)